A polysaccharide helps protect against mycoplasmal pneumonia
The substance Ganoderma lucidum polysaccharide GLFP2 works through the gut-lung axis to reduce lung inflammation.
Oral Ganoderma lucidum polysaccharide GLFP2 alleviated mycoplasmal pneumonia in mice. This substance works through the gut-lung axis.
Researchers used enzymatic fragmentation and multidimensional NMR analysis to resolve the structure of GLFP2. They identified -(16)-linked galactosyl motifs as key structural features.
GLFP2 reshaped the gut microbiota. It also functionally reprogrammed gut microbiota-derived extracellular vesicles (GMEVs).
GMEVs are vesicles derived from the gut microbiota. These vesicles showed systemic exposure and associated with the lung.
The vesicles were taken up by alveolar macrophages. This process activated AMP-activated protein kinase (AMPK) signaling and suppressed the S100A8/A9 inflammatory axis.
This action limited neutrophil-driven immunopathology. Respiratory infections remain a major global health challenge due to antibiotic resistance.
Key facts
- GLFP2 contains -(16)-linked galactosyl motifs.
- GMEVs can confer pulmonary protection when transplanted.
- Orally administered GMEVs were taken up by alveolar macrophages.